{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-022060","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.532098+00:00","generated_at":"2026-06-05T08:07:27.195925+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Standard BioTools FY2023 revenue $106M (+9%); Q4 gross margin 59.6%; SomaLogic merger closed","bullets":["FY2023 revenue $106.3M (+9% YoY); Q4 revenue $28.2M (+4%); instrument sales +46% for FY.","Non-GAAP gross margin 60.1% for FY2023 (+900 bps YoY); net loss $74.7M.","Non-GAAP adjusted EBITDA loss improved $34M to $34.7M; operating cash use down 53%.","Combined pro forma 2023 revenue ~$192M; pro forma cash $565M (incl. SomaLogic's $449.8M).","Merger with SomaLogic closed Jan 5, 2024; integration underway; CEO cites disciplined execution."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-022060","json":"https://secwatch.observer/filing/0000950170-24-022060.json","markdown":"https://secwatch.observer/filing/0000950170-24-022060.md","text":"https://secwatch.observer/filing/0000950170-24-022060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000095017024022060/0000950170-24-022060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000095017024022060/lab-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:07:27.195925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e405d825bae040afdff3eb9bd8485142711f2353","claim":"STANDARD BIOTOOLS INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $28.2, net income $(19.8).","evidence_excerpt":"2023 Fourth Quarter and Full Year Selected Financial Results 2 Quarter Ended Year Ended (Unaudited, in millions, except percentages) December 31, 2023 December 31, 2023 Revenue $ 28.2 $ 106.3 GAAP gross margin 47.4 % 47.4 % Non-GAAP gross margin 59.6 % 60.1 % Operating expenses $ 34.7 $ 127.1 Non-GAAP operating expenses $ 24.3 $ 98.6 Operating loss $ (21.4 ) $","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000095017024022060/0000950170-24-022060-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$28.2"},{"label":"Net income","value":"$(19.8)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}